I Tabah

Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte.

Pauline Brice, Y Bastion, Éric Lepage et al. · Journal of Clinical Oncology · 1997 · 641 citations

Medicine, Hematology, Oncology +13

Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial.

Alain Ravaud, Christine Chevreau, Laurent Cany et al. · Journal of Clinical Oncology · 1998 · 53 citations

Life Sciences, Immunology, Oncology +17

Human recombinant granulocyte‐macrophage colony stimulating factor (hrGM‐CSF) improves double hemibody irradiation (DHBI) tolerance in patients with stage III multiple myeloma: A pilot study

Xavier Troussard, Margaret Macro, B. Vie et al. · British Journal of Haematology · 1995 · 17 citations

Medicine, Hematology, Oncology +17

Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patients

Thierry Philip, Sylvie Négrier, Christine Lasset et al. · British Journal of Cancer · 1993 · 16 citations · Full text

Medicine, Immunology, Oncology +14

Granulocyte-macrophage colony-stimulating factor accelerates hematopoietic recovery after autologous bone marrow or peripheral blood progenitor cell transplantation and high-dose chemotherapy for lymphoma.

P Colombat, Martine Delain, Isabelle Desbois et al. · PubMed · 1996 · 13 citations

Medicine, Hematology, Immunology +16